US company second to report impressive efficacy for its COVID-19 vaccine candidate.
Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from Phase 3 study.
New study finds coronaviruses are masters of mimicry, reproducing their host’s immune proteins to remain invisible and help promote infection.
Researchers enhance the immune response against the receptor binding domain of SARS-CoV-2 by presenting it on liposomes, providing a promising strategy for vaccine development targeting this domain.
Measures that could have been taken at the beginning of the pandemic were not implemented as precautionary preparation but rather as reactionary to an already spreading virus, making it hard to contain.
SARS-CoV-2 antibodies were found in patients’ blood up to 7 months after infection, and researchers are hopeful.
A small trial indicates that Moderna’s experimental SARS-CoV-2 vaccine is effective and safe in older adults, a population group most vulnerable to severe COVID-19.
Where pneumococcal vaccination rates are high, COVID-19 cases are low and vice-versa.
Researchers capture high-powered microscopic images showing startlingly high SARS-CoV-2 viral loads on human respiratory surfaces.
The global trial run by researchers at Oxford and AstraZeneca has been paused due to an adverse reaction at a UK site. Whether the reaction is related to the vaccine is still unknown.